Cargando…

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens

Sipuleucel-T, an autologous cellular immunotherapy, was approved to treat metastatic castration-resistant prostate cancer in 2010 in the United States. Treatment with sipuleucel-T primes the immune system to target prostate acid phosphatase, which is expressed by prostate cancer cells, potentially l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kibel, Adam S, Inman, Brant A, Pachynski, Russell K, Vu, Tuyen, Sheikh, Nadeem A, Petrylak, Daniel P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826523/ https://www.ncbi.nlm.nih.gov/pubmed/33630063 http://dx.doi.org/10.1093/jnci/djab025

Ejemplares similares

Induction of antigen spread after sipuleucel-T treatment and its association with improved clinical outcome
por: GuhaThakurta, Debraj, et al.
Publicado: (2013)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
por: Sheikh, Nadeem A., et al.
Publicado: (2012)

Sipuleucel-T: immunotherapy for advanced prostate cancer
por: Olson, Brian M, et al.
Publicado: (2011)

Immune Response to Sipuleucel-T in Prostate Cancer
por: Thara, Eddie, et al.
Publicado: (2012)

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2014)

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T
por: Small, E J, et al.
Publicado: (2014)

Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
por: Madan, Ravi A, et al.
Publicado: (2020)

Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
por: Sutherland, Sarah I. M., et al.
Publicado: (2021)

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
por: Drake, Charles G, et al.
Publicado: (2015)

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
por: Bitting, Rhonda L., et al.
Publicado: (2011)

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
por: Huber, Marie L., et al.
Publicado: (2012)

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
por: Gulley, James L., et al.
Publicado: (2015)

To Lyse or Not to Lyse: Transient-Mediated Stochastic Fate Determination in Cells Infected by Bacteriophages
por: Joh, Richard I., et al.
Publicado: (2011)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Pachynski, Russell K, et al.
Publicado: (2021)

The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
por: Ng, Laura, et al.
Publicado: (2013)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
por: Caram, Megan E. V., et al.
Publicado: (2019)

Recurrent Bilateral Strokes in a Patient Treated With Sipuleucel-T for Prostate Cancer
por: Gill, Jashan, et al.
Publicado: (2021)

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
por: Graff, Julie N, et al.
Publicado: (2014)

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2012)

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
por: Gulley, James L., et al.
Publicado: (2017)

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
por: Yi, Renliang, et al.
Publicado: (2016)

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer
por: Hagihara, Katsunobu, et al.
Publicado: (2018)

Murine Cytotoxic T Lymphocytes Recognize an Epitope in an EBNA-1 Fragment, but Fail to Lyse EBNA-1–expressing Mouse Cells
por: Mukherjee, Siddhartha, et al.
Publicado: (1998)

Chromosome movement in lysed mitotic cells is inhibited by vanadate
Publicado: (1978)

Syndrome de lyse tumorale
por: Grewal, Keerat, et al.
Publicado: (2023)

Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
por: Ma, Chaoran, et al.
Publicado: (2023)

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry
por: Sartor, Oliver, et al.
Publicado: (2020)

A comparison of Lyse-It to other cellular sample preparation, bacterial lysing, and DNA fragmentation technologies
por: Santaus, Tonya M., et al.
Publicado: (2019)

Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
por: Sims, Robert B.
Publicado: (2011)

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
por: McKay, Rana R., et al.
Publicado: (2020)

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
por: Holl, Eda K., et al.
Publicado: (2019)

Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
por: Dehdashti, Farrokh, et al.
Publicado: (2022)

MAIT Cells Detect and Efficiently Lyse Bacterially-Infected Epithelial Cells
por: Le Bourhis, Lionel, et al.
Publicado: (2013)

Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
por: Gupta, Shilpa, et al.
Publicado: (2011)

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer
por: Hannan, Raquibul, et al.
Publicado: (2022)

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2019)

Tumor Lysing Genetically Engineered T Cells Loaded with Multi-Modal Imaging Agents
por: Bhatnagar, Parijat, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ebm23rsdgtbl65fcv9gpq10s2t